RxDoctor Payments Data

Dawn Cooper

Family · Sewell, NJNPI 1558731497

Payments from drug & device makers

$849in general payments, 2019–2025

Across 42 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$173
  • Exact Sciences$149
  • GSK$127
  • Pfizer$119
  • Astellas Pharma US Inc$108
  • Novo Nordisk$68
  • plus $104 from 4 others

What the payments were for

  • Food & beverage$849100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$849 in reported general payments places this provider in the 70th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$57,663
Medicare patients
254
Services billed
825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$71,146
EliquisApixaban60$63,292
JardianceEmpagliflozin15$25,164
XareltoRivaroxaban24$24,332
Breo ElliptaFluticasone/Vilanterol27$12,896
FarxigaDapagliflozin Propanediol11$12,516
MounjaroTirzepatide11$12,066
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,823
OxycontinOxycodone Hcl12$11,143
Tresiba Flextouch U-100Insulin Degludec15$7,799
MyrbetriqMirabegron13$6,194
Atorvastatin Calcium420$4,398
Albuterol Sulfate HfaAlbuterol Sulfate140$3,839
Levothyroxine Sodium280$3,119
Advair HfaFluticasone Propion/Salmeterol13$2,962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$68$71,14663 claims
PfizerEliquis$119$63,29260 claims
GSKBreo Ellipta, Trelegy Ellipta$127$24,71938 claims
AstraZenecaFarxiga$45$12,51611 claims
Lilly USA, LLCMounjaro$19$12,06611 claims
Astellas Pharma US IncMyrbetriq$108$6,19413 claims
AbbVieSynthroid$173$1,23927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,692 family providers in New Jersey.

Other family in Sewell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →